At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02137 BRII-B
Not Yet Opened 12-20 16:08:10
0.850
-0.010
-1.16%
High0.900Low0.830Vol542.00K
Open0.840D1 Closing0.860Amplitude8.14%
Mkt Cap621.35MTradable Cap621.35MTotal Shares731.00M
T/O465.06KT/O Rate0.07%Tradable Shares731.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Brii Biosciences Launches HK$60 Million Buyback Program
MT Newswires Live  ·  12-20 19:36
Brii Biosciences Launches HK$60 Million Buyback Program
Brii Biosciences Ltd - Chairman Obtained Approval to Acquire No More Than 2 Mln Shares
THOMSON REUTERS  ·  12-20 16:47
Brii Biosciences Ltd - Chairman Obtained Approval to Acquire No More Than 2 Mln Shares
Brii Biosciences - Undertaking on-Market Buy-Back Programme With Total Amount of Funds No More Than HK$60 Mln
THOMSON REUTERS  ·  12-20 16:47
Brii Biosciences - Undertaking on-Market Buy-Back Programme With Total Amount of Funds No More Than HK$60 Mln
Brii Biosciences Records Wider Loss in H1 on Nil Revenue
MT Newswires Live  ·  08-19
Brii Biosciences Records Wider Loss in H1 on Nil Revenue
Brii Biosciences Records Wider Loss in H1 on Nil Revenue
MT Newswires Live  ·  08-19
Brii Biosciences Records Wider Loss in H1 on Nil Revenue
BRIEF-Brii Biosciences Posts HY Loss RMB283.2 Million
Reuters  ·  08-19
BRIEF-Brii Biosciences Posts HY Loss RMB283.2 Million
Brii Biosciences - Hy Loss RMB283.2 Mln
THOMSON REUTERS  ·  08-19
Brii Biosciences - Hy Loss RMB283.2 Mln
Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%
MT Newswires Live  ·  07-31
Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%
Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%
MT Newswires Live  ·  07-31
Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%
BRIEF-Brii Biosciences Says On July 30, VBI Vaccines Initiated Restructuring Proceedings
Reuters  ·  07-31
BRIEF-Brii Biosciences Says On July 30, VBI Vaccines Initiated Restructuring Proceedings
Brii Biosciences Ltd - on July 30, VBI Vaccines Initiated Restructuring Proceedings
THOMSON REUTERS  ·  07-31
Brii Biosciences Ltd - on July 30, VBI Vaccines Initiated Restructuring Proceedings
Brii Biosciences - Does Not Expect Material Impacts on Its Business Operation and Financial Performance Due to VBI's Insolvency
THOMSON REUTERS  ·  07-31
Brii Biosciences - Does Not Expect Material Impacts on Its Business Operation and Financial Performance Due to VBI's Insolvency
Institutions profited after Brii Biosciences Limited's (HKG:2137) market cap rose HK$109m last week but individual investors profited the most
Simply Wall St.  ·  07-18
Institutions profited after Brii Biosciences Limited's (HKG:2137) market cap rose HK$109m last week but individual investors profited the most

Introduction

Company Name.
BRII-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Issue price:
--